ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
6,025.99
-0.95%
Dow Jones
44,303.40
-0.99%
US Dollar vs MXN
20.5714
0.00%
Brent Oil
74.565
0.00%
Bitcoin
96,862.73
0.42%
Pepperstone
Advertisement
Registration Strip Icon for alerts Regístrate para obtener alertas en tiempo real, cartera personalizada y movimientos del mercado.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ

  6. Atossa Therapeutics Inc (ATOS) Cotización

Atossa Therapeutics Inc

Atossa Therapeutics Inc (ATOS)

NASDAQ
0.7654
-0.0396
(-4.92%)
Cerrado 09 Febrero 3:00PM
Delayed by 15 minutes
0.77
0.0046
(0.60%)
Fuera de horario: 6:15PM
Delayed by 15 minutes

Su centro para precios en tiempo real, ideas y debates en vivo

Premium

Estadísticas y detalles clave

Último Precio
0.77
Postura de Compra
0.77
Postura de Venta
0.7869
Volume Operado de la Acción
781,285
0.7611 Rango del Día 0.8199
0.7203 Rango de 52 semanas 2.31
Capitalización de Mercado [m]
96.867M
Precio Anterior
0.805
Precio de Apertura
0.8058
Hora
5
@
0.77
Última hora de negociación
Volumen financiero
US$ 617,417
Precio Promedio Ponderado
0.790258
Volumen promedio (3 m)
858,893
Acciones en circulación
125,801,254
Rendimiento del Dividendo
-
Ratio Precio/Utilidad
-3.22
Beneficio por acción (BPA)
-0.24
turnover
-
Beneficio neto
-30.09M

Acerca de Atossa Therapeutics Inc

Atossa Therapeutics Inc is a clinical-stage pharmaceutical company operating in us. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other brea... Atossa Therapeutics Inc is a clinical-stage pharmaceutical company operating in us. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use. Mostrar más

Sector
Pharmaceutical Preparations
Industria
Pharmaceutical Preparations
Sitio web
www.atossatherapeutics.com
Sede
Wilmington, Delaware, USA
Fundado
-
Atossa Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker ATOS. The last closing price for Atossa Therapeutics was US$0.81. Over the last year, Atossa Therapeutics shares have traded in a share price range of US$ 0.7203 to US$ 2.31.

Atossa Therapeutics currently has 125,801,254 shares in issue. The market capitalisation of Atossa Therapeutics is US$101.27 million. Atossa Therapeutics has a price to earnings ratio (PE ratio) of -3.22.

ATOS Últimas noticias

Más noticias

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

07 Febrero 2025
Edgar (US Regulatory)

Atossa Therapeutics Congratulates Board Director Dr. Tessa Cigler and Weill Cornell Medicine on CDC Grant to Enhance Breast Cancer Care

SEATTLE, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the prevention and...

05 Febrero 2025
GlobeNewswire Inc.

Form 8-K - Current report

04 Febrero 2025
Edgar (US Regulatory)

Atossa Therapeutics Responds to PTAB Ruling on U.S. Patent No. 11,572,334 and Announces the Issuance of U.S. Patent No. 12,201,591

SEATTLE, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the prevention and...

30 Enero 2025
GlobeNewswire Inc.

Atossa Therapeutics Issues Letter to Shareholders Highlighting 2024 Accomplishments and Outlook for 2025

SEATTLE, Jan. 23, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the prevention and...

23 Enero 2025
GlobeNewswire Inc.

Atossa Therapeutics Applauds U.S. Surgeon General’s Advisory Highlighting Alcohol as a Leading Preventable Cause of Breast Cancer

SEATTLE, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the prevention and...

06 Enero 2025
GlobeNewswire Inc.

Atossa Therapeutics to Present Poster Describing the Discovery of Molecules Synergistic with (Z)-endoxifen for the Treatment of Breast Cancer at the 2024 San Antonio Breast Cancer Symposium

SEATTLE, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), a clinical stage biopharmaceutical company developing innovative medicines in...

12 Diciembre 2024
GlobeNewswire Inc.

Atossa Therapeutics Announces Full Results from Phase 2 KARISMA-Endoxifen Study Demonstrating Statistically Significant Reductions in Mammographic Breast Density

1 MG Dose (Z)-Endoxifen Shows Potential as a Well-Tolerated, Preventative Therapy for Premenopausal Women at Risk of Developing Breast Cancer Data to be Presented in a Poster Spotlight Session...

11 Diciembre 2024
GlobeNewswire Inc.

Form 8-K - Current report

10 Diciembre 2024
Edgar (US Regulatory)

Atossa Therapeutics to Present Pharmacokinetic and Tolerability Data from Phase 2 EVANGELINE Trial at the 2024 San Antonio Breast Cancer Symposium

SEATTLE, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), a clinical stage biopharmaceutical company developing innovative medicines in...

10 Diciembre 2024
GlobeNewswire Inc.
Período †Variación(Ptos)Variación %AperturaPrecio MáximoPrecio MínimoAvg. Vol. diarioPrecio Promedio Ponderado
1-0.1-11.49425287360.870.91790.776390530.83633695CS
4-0.19-19.79166666670.960.97720.72038140070.87109167CS
12-0.61-44.20289855071.381.380.72038588931.0399751CS
26-0.46-37.39837398371.231.660.72036743261.20922403CS
52-0.1399-15.37531596880.90992.310.720310876981.39613393CS
156-0.53-40.76923076921.32.310.59094821.17721539CS
260-0.72-48.3221476511.499.80.536134403.11905398CS

ATOS - Preguntas Frecuentes

¿Cuál es el precio actual de las acciones de Atossa Therapeutics?
El precio actual de las acciones de Atossa Therapeutics es US$ 0.77
¿Cuántas acciones de Atossa Therapeutics están en circulación?
Atossa Therapeutics tiene 125,801,254 acciones en circulación
¿Cuál es la capitalización de mercado de Atossa Therapeutics?
La capitalización de mercado de Atossa Therapeutics es USD 101.27M
¿Cuál es el rango de negociación de 1 año para el precio de las acciones de Atossa Therapeutics?
Atossa Therapeutics ha negociado en un rango de US$ 0.7203 a US$ 2.31 durante el último año
¿Cuál es el ratio PE (precio/beneficio) de Atossa Therapeutics?
El ratio precio/beneficio de Atossa Therapeutics es -3.22
¿Cuál es la moneda de reporte de Atossa Therapeutics?
Atossa Therapeutics presenta sus resultados financieros en USD
¿Cuál es el último beneficio anual de Atossa Therapeutics?
El último beneficio anual de Atossa Therapeutics es USD -30.09M
¿Cuál es la dirección registrada de Atossa Therapeutics?
La dirección registrada de Atossa Therapeutics es 251 LITTLE FALLS DRIVE, WILMINGTON, DELAWARE, 19808
¿Cuál es la dirección del sitio web de Atossa Therapeutics?
La dirección del sitio web de Atossa Therapeutics es www.atossatherapeutics.com
¿En qué sector industrial opera Atossa Therapeutics?
Atossa Therapeutics opera en el sector PHARMACEUTICAL PREPARATIONS

Movimientos

Ver todo
  • Volumen
  • % Mayores Alzas
  • % Mayores Bajas
SímboloPrecioVol.
MGOLMGO Global Inc
US$ 0.4191
(126.54%)
780.46M
CDTConduit Pharmaceuticals Inc
US$ 2.831
(82.65%)
140.32M
GSIWGarden Stage Ltd
US$ 0.79
(78.73%)
215.16M
TOIIWOncology Institute Inc
US$ 0.033
(58.88%)
7.27k
CYTHCyclo Therapeutics Inc
US$ 1.19
(54.55%)
72.39M
FTELFitell Corporation
US$ 2.70
(-57.01%)
2.28M
SGBXSafe and Green Holdings Corporation
US$ 0.6401
(-44.82%)
5.15M
NKLANikola Corporation
US$ 0.4432
(-41.10%)
47.43M
PLRXPliant Therapeutics Inc
US$ 7.785
(-34.85%)
6.4M
LIPOLipella Pharmaceuticals Inc
US$ 3.08
(-33.76%)
2.08M
MGOLMGO Global Inc
US$ 0.4191
(126.54%)
816.59M
RIMEAlgorhythm Holdings Inc
US$ 0.0169
(-20.66%)
274.2M
NVDANVIDIA Corporation
US$ 129.84
(0.90%)
228.2M
GSIWGarden Stage Ltd
US$ 0.79
(78.73%)
219.64M
BHATBlue Hat Interactive Entertainment Technology
US$ 0.0537
(14.74%)
212.29M

ATOS Discussion

Ver más
eb0783 eb0783 2 semanas hace
Atossa Therapeutics Issues Letter to Shareholders Highlighting 2024 Accomplishments and Outlook for 2025.

https://investors.atossatherapeutics.com/news-releases/news-release-details/atossa-therapeutics-issues-letter-shareholders-highlighting-2024
👍️0
glenn1919 glenn1919 2 semanas hace
ATOS.........................https://stockcharts.com/h-sc/ui?s=ATOS&p=W&b=5&g=0&id=p86431144783
👍️0
XenaLives XenaLives 5 meses hace
Why on earth did it take me so long to find this?



Following...

https://x.com/stevenquay
👍️0
XenaLives XenaLives 5 meses hace
I think I'm in love... LOL!!!



Historical perspective:

👍️0
XenaLives XenaLives 5 meses hace
More interesting...

https://stockcharts.com/h-sc/ui?s=ATOS&p=W&b=5&g=0&id=p86431144783
👍️0
XenaLives XenaLives 5 meses hace
ATOS chart...

👍️0
XenaLives XenaLives 5 meses hace
Interesting .. also from Google...

A response to this query...

what is unique about atossa therapeutics inc

Response...

Is Atossa Therapeutics a good buy?
Why is Atossa stock dropping?
Who owns Atossa Therapeutics?
What is the target price for Atossa Genetics?
Stock Price Target ATOS
High $6.25
Median $6.00
Low $4.00
Average $5.42
Current Price $1.39

ATOS | Atossa Therapeutics Inc. Analyst Estimates & Rating - WSJ

WSJ
https://www.wsj.com › quotes › ATOS › research-ratings
Search for: What is the target price for Atossa Genetics?
What is the stock price forecast for Atossa Therapeutics in 2025?
What does Atossa Therapeutics do?


👍️0
XenaLives XenaLives 5 meses hace
From Google Generative AI:


Atossa Therapeutics is a clinical-stage biopharmaceutical company that develops innovative medicines for oncology, with a focus on breast cancer and other breast conditions. Some unique aspects of Atossa Therapeutics include:
Patented (Z)-endoxifen
Atossa has patented the chemical process and composition of matter for (Z)-endoxifen, as well as a patented oral enteric capsule formulation.
Phase 2 I-SPY 2 Clinical Trial
Atossa is fully enrolling this trial, which is evaluating (Z)-endoxifen as a neoadjuvant treatment for patients with newly diagnosed estrogen receptor-positive breast cancer.
Phase 2 trials
Atossa is currently studying (Z)-endoxifen in four Phase 2 trials, including one in healthy women with measurable breast density, one in women diagnosed with ductal carcinoma in situ, and two other studies.
U.S. patents
Atossa's (Z)-endoxifen is protected by three issued U.S. patents and numerous pending patent applications.
👍️0
XenaLives XenaLives 5 meses hace
Intriguing science...
👍️0
XenaLives XenaLives 5 meses hace

(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer

https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2023-00701&r=1
👍️0
XenaLives XenaLives 5 meses hace
Link to Atossa pipeline...
https://atossatherapeutics.com/product-pipeline/
👍️0
XenaLives XenaLives 5 meses hace
Following - some valid science is going on here...
👍️0
glenn1919 glenn1919 6 meses hace
ATOS....................................https://stockcharts.com/h-sc/ui?s=ATOS&p=W&b=5&g=0&id=p86431144783
👍️0
glenn1919 glenn1919 7 meses hace
ATOS.........................https://stockcharts.com/h-sc/ui?s=ATOS&p=W&b=5&g=0&id=p86431144783
👍️0
glenn1919 glenn1919 7 meses hace
ATOS...............................https://stockcharts.com/h-sc/ui?s=ATOS&p=W&b=5&g=0&id=p86431144783
👍️0
glenn1919 glenn1919 9 meses hace
ATOS..................................https://stockcharts.com/h-sc/ui?s=ATOS&p=W&b=5&g=0&id=p86431144783
👍️ 1
Joeyohso Joeyohso 10 meses hace
Also no debt and 90m+ in cash. That is unheard of for a research pharma company. They also are extending the employee stock purchase program for all of 2024. This stock is a gem
👍️0
ShadowDiviner72 ShadowDiviner72 10 meses hace
New PR, and data release shows that Endoxifen does not only stop the tumor from growing...

It even shows that it eliminates the tumor !!!!!! They cured a patient from breast cancer by taking a simple pill during 6 months!

INCREDIBLE
👍️0
glenn1919 glenn1919 10 meses hace
ATOS...........................................https://stockcharts.com/h-sc/ui?s=ATOS&p=W&b=5&g=0&id=p86431144783
👍️0
Joeyohso Joeyohso 10 meses hace
Why the dump today? I was able to grab some at 1.65
👍️0
Monksdream Monksdream 10 meses hace
Early Barchart 100
https://www.barchart.com/stocks/performance/percent-change/advances?orderBy=percentChange&orderDir=desc
👍️0
Monksdream Monksdream 10 meses hace
ATOS new 52 hi
👍️0
Monksdream Monksdream 10 meses hace
ATOS 10Q due 4/5
👍️0
Monksdream Monksdream 11 meses hace
ATOS new 52 hi
👍️0
glenn1919 glenn1919 11 meses hace
ATOS..................................https://stockcharts.com/h-sc/ui?s=ATOS&p=W&b=5&g=0&id=p86431144783
👍️0
TrendTrade2016 TrendTrade2016 11 meses hace
ATOS..LEVEL 2 LOOKING VERY NICE IN PRE
👍️0
TrendTrade2016 TrendTrade2016 11 meses hace
ATOS...GET READY TO RUMBLE...WE ARE LOCKED IN AND LOADED TO 1.73
👍️0
glenn1919 glenn1919 11 meses hace
ATOS.............................https://stockcharts.com/h-sc/ui?s=ATOS&p=W&b=5&g=0&id=p86431144783
👍️0
glenn1919 glenn1919 11 meses hace
ATOS.........................................https://stockcharts.com/h-sc/ui?s=ATOS&p=W&b=5&g=0&id=p86431144783
👍️0
glenn1919 glenn1919 12 meses hace
ATOS..................................https://stockcharts.com/h-sc/ui?s=ATOS&p=W&b=5&g=0&id=p86431144783
👍️0
glenn1919 glenn1919 1 año hace
ATOS................https://stockcharts.com/h-sc/ui?s=ATOS&p=W&b=5&g=0&id=p86431144783
👍️0
Birdbrain Ideas Birdbrain Ideas 2 años hace
There hasn't been a post on this board in six weeks. If these Stage 2 trials turn out well, this board will light up along with the share price.
👍️0
Laster Laster 2 años hace
I loved that wall at $1.04 yesterday. It was calling my name. I was too slow.
Then it was taken out. I wasn’t too upset because….
I was lucky enough for another wall at $1.05 that I helped take out. Then boom.
Chart looked good. News good. Repurchase plan news excellent.
What’s not to like.
Hope to see if move back above $2.
Good luck.
👍️0
tw0122 tw0122 2 años hace
Looking good. Hidden gem not any longer
👍️0
killrEngineer killrEngineer 2 años hace
Wow. No comments?
10 million share repurchase announcement yesterday and study enrollment announcement today.
👍️0
DrJinx DrJinx 2 años hace
This aged like milk. How's that priming for a big run up working out for you? Maybe someday people will realize the company is smoke and mirrors. Keep in mind your CEO is old as F, he dies... this thing tanks even harder.
👍️0
Engle1488 Engle1488 3 años hace
We are primed for a big run up people. In at 1.04
👍️0
Agreed Agreed 3 años hace
The market cap is less than their holdings in cash...clearly undervalued.
👍️0
Agreed Agreed 3 años hace
Insider buying by CEO and CFO, new patent protections...looking promising.
👍️0
DollarSquad DollarSquad 3 años hace
Yes. You likely lost a lot of money. This investment is worthless. RMSL
👍️0
4MVault 4MVault 3 años hace
Did something just happen?
👍️0
slugo1 slugo1 3 años hace
Looking for bottom here
👍️0
ttottip ttottip 3 años hace
Yes, very soon. This will reverse the trend.
👍️0
slugo1 slugo1 3 años hace
Soon
👍️0
ttottip ttottip 3 años hace
Soon the 2.5's , 2.6's .....
👍️0
slugo1 slugo1 3 años hace
Yes
👍️0
ttottip ttottip 3 años hace
The 2.6's on the horizon.
👍️0
slugo1 slugo1 3 años hace
That's one of the things I like about them Also there should be some updates coming
👍️0
ttottip ttottip 3 años hace
140 millions of dollars cash? ATOS can do great things with this money.
👍️0
slugo1 slugo1 3 años hace
Nice buy worth alot when this hits $10.00
👍️0

Su Consulta Reciente

NASDAQ
ATOS
Atossa Therapeutics
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2025 ADVFN PLC - Todos los derechos reservados

Quitar anuncios

Suscríbete a una experiencia sin publicidad

Sin anuncios

Pruébalo ahora

Mantenga los anuncios